RAPT Therapeutics (NASDAQ:RAPT) Upgraded by Wall Street Zen to "Hold" Rating

Wall Street Zen upgraded shares of RAPT Therapeutics (NASDAQ:RAPT - Free Report) from a sell rating to a hold rating in a report published on Thursday morning.

Several other research firms also recently commented on RAPT. HC Wainwright raised shares of RAPT Therapeutics to a "strong-buy" rating and set a $6.00 target price on the stock in a report on Thursday, May 22nd. UBS Group lowered their target price on shares of RAPT Therapeutics from $2.00 to $1.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $3.00.

RAPT Therapeutics Stock Performance

Shares of RAPT traded down $0.26 during mid-day trading on Thursday, reaching $0.97. The stock had a trading volume of 1,996,770 shares, compared to its average volume of 1,281,097. The firm has a market cap of $128.19 million, a price-to-earnings ratio of -0.35 and a beta of -0.04. RAPT Therapeutics has a 12 month low of $0.71 and a 12 month high of $4.60. The business has a fifty day moving average of $0.98 and a 200 day moving average of $1.14.

RAPT Therapeutics (NASDAQ:RAPT - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.31) by $0.23. On average, research analysts forecast that RAPT Therapeutics will post -2.14 EPS for the current fiscal year.

Institutional Investors Weigh In On RAPT Therapeutics

A number of hedge funds have recently bought and sold shares of RAPT. Simplicity Wealth LLC purchased a new stake in RAPT Therapeutics during the first quarter valued at $25,000. Picton Mahoney Asset Management raised its stake in RAPT Therapeutics by 994.4% during the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after purchasing an additional 14,697 shares in the last quarter. JPMorgan Chase & Co. raised its stake in RAPT Therapeutics by 298.2% during the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company's stock valued at $34,000 after purchasing an additional 25,130 shares in the last quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC purchased a new stake in RAPT Therapeutics during the fourth quarter valued at $63,000. Finally, Sei Investments Co. purchased a new stake in RAPT Therapeutics during the fourth quarter valued at $64,000. Hedge funds and other institutional investors own 99.09% of the company's stock.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.